Autopsy report · NCT05489679
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Cause of deathFunding or business
“Voluntarily terminate the study since the sponsor's development strategy was adjusted.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Accutar Biotechnology Inc
- Sponsor type
- Industry
- Conditions
- Breast Cancer
- Interventions
- AC682
- Participants
- 6
- Sites
- 3
- Countries
- China
Trials that died the same way
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
“Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.” - Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
“The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.” - A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
“The study was terminated due to the sponsor's research and development strategy adjustment.” - Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - Study of Viziatek ISL™ Refractive Phakic Intra Sulcus Lens for Refraction Adjustment in Blind Volunteers
“Sponsor decision to terminate the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.